LGND Key Statistics, Chart & Performance
The current stock price of LGND is 183.13 USD. In the past month the price decreased by -10.93%. In the past year, price increased by 56.64%.
LGND Latest News, Press Relases and Analysis
LGND Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.9 | 954.25B | ||
| JNJ | JOHNSON & JOHNSON | 20.23 | 505.98B | ||
| MRK | MERCK & CO. INC. | 11.24 | 245.74B | ||
| PFE | PFIZER INC | 8.06 | 146.69B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.8 | 104.23B | ||
| ZTS | ZOETIS INC | 18.56 | 51.85B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.44 | 22.40B | ||
| VTRS | VIATRIS INC | 4.97 | 13.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.16 | 10.57B | ||
| CORT | CORCEPT THERAPEUTICS INC | 99.01 | 9.17B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.50B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.24B |
Related stock screener links
About LGND
Company Profile
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. The company is headquartered in Jupiter, Florida and currently employs 68 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Company Info
LIGAND PHARMACEUTICALS
555 Heritage Drive, Suite 200
Jupiter FLORIDA 92121 US
CEO: John L. Higgins
Employees: 68
Phone: 18585507500
LIGAND PHARMACEUTICALS / LGND FAQ
What does LIGAND PHARMACEUTICALS do?
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. The company is headquartered in Jupiter, Florida and currently employs 68 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Can you provide the latest stock price for LIGAND PHARMACEUTICALS?
The current stock price of LGND is 183.13 USD. The price decreased by -0.49% in the last trading session.
Does LIGAND PHARMACEUTICALS pay dividends?
LGND does not pay a dividend.
What is the ChartMill technical and fundamental rating of LGND stock?
LGND has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is LIGAND PHARMACEUTICALS (LGND) stock traded?
LGND stock is listed on the Nasdaq exchange.
What is the employee count for LGND stock?
LIGAND PHARMACEUTICALS (LGND) currently has 68 employees.
What is the market capitalization of LGND stock?
LIGAND PHARMACEUTICALS (LGND) has a market capitalization of 3.60B USD. This makes LGND a Mid Cap stock.
LGND Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to LGND. When comparing the yearly performance of all stocks, LGND is one of the better performing stocks in the market, outperforming 89.36% of all stocks.
LGND Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to LGND. LGND scores excellent on profitability, but there are some minor concerns on its financial health.
LGND Financial Highlights
Over the last trailing twelve months LGND reported a non-GAAP Earnings per Share(EPS) of 7.29. The EPS increased by 25.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.34% | ||
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| Debt/Equity | 0.47 |
LGND Forecast & Estimates
13 analysts have analysed LGND and the average price target is 242.25 USD. This implies a price increase of 32.28% is expected in the next year compared to the current price of 183.13.
For the next year, analysts expect an EPS growth of 35.02% and a revenue growth 57.16% for LGND